Back

Serial ai based comprehensive coronary physiological assessment before and after intensive lipid lowering therapy: YELLOW III substudy

29 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Physiological assessment of coronary circulation Intracoronary Flow and Pressure Measurements ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Pruthvi C Revaiah

New York (United States of America)

6 More presentations in this session

Presentation thumbnail
The RFR-FFR delta: a novel physiological signature of microvascular dysfunction and long-term mortality in patients undergoing LAD PCI
Doctor T. Watanabe (Tsuchiura, JP)
Abstract Slides Video
Presentation thumbnail
Impact of pullback pressure gradient on clinical outcomes after percutaneous coronary interventions
Doctor D. Munhoz (Aalst, BE)
Abstract Slides Video
Presentation thumbnail
Vessel specific discrepancies between visual assessment and resting and hyperemic physiological indices
Doctor A. Agoston (Nyiregyhaza, HU)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of angiographically morphology in functionally non-significant coronary stenosis
Doctor H. Kirigaya (Yokohama, JP)
Abstract Slides Video
Presentation thumbnail
Spatial Heterogeneity of Coronary Microvascular Dysfunction in ANOCA: Potential Clinical Impact of Multivessel Concordance in CFR and MRR
Doctor T. Watanabe (Tsuchiura, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Physiological assessment of coronary circulation

The Event

Event poster

ESC Congress 2026

29 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial
1 September 2025
thumbnail
Congress Presentation
Evaluation of epicardial coronary resistance using computed tomography angiography
31 August 2019
thumbnail
Congress Presentation
Percutaneous coronary intervention in acute coronary syndrome should be physiology-guided: pro
30 August 2026
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources